SCM
VRTX icon

Suffolk Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Suffolk Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-102,203
Closed -$9.68M – 160
2014
Q2 		$9.68M Sell
102,203
-68,307
-40% -$4.79M 1.17% 35
2014
Q1 		$12.1M Buy
170,510
+37,460
+28% +$2.97M 1.49% 24
2013
Q4 		$9.89M Sell
133,050
-11,250
-8% -$783K 1.24% 30
2013
Q3 		$10.9M Sell
144,300
-20,470
-12% -$1.63M 1.47% 29
2013
Q2 		$13.2M Buy
+164,770
New +$12.1M 1.9% 6

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Suffolk Capital Management's VRTX Position: Q3 2014 in Review

Suffolk Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2014, closing a stake of 102,203 shares — an estimated $9.68M sold.

Suffolk Capital Management first reported a position in VRTX in Q2 2013 and held it in 5 quarters. The position peaked at $13.2M in Q2 2013. 431 funds tracked by Wall St. Rank hold VRTX as of Q3 2014.

  • Suffolk Capital Management reported no remaining Vertex Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Suffolk Capital Management sold 102,203 Vertex Pharmaceuticals shares in Q3 2014, an estimated $9.68M.
  • Suffolk Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 5 quarters.
  • Suffolk Capital Management's Vertex Pharmaceuticals position peaked at $13.2M in Q2 2013.
  • 431 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2014.

Based on Suffolk Capital Management's 13F filing for Q3 2014, filed 5 Nov 2014.